Since January 2020, the world has been experiencing the impact of COVID-19. The rapidly evolving COVID-19 pandemic has hospitals and acute care facilities changing standard operating procedures. As a result, wound care services, procedures and surgeries are undergoing considerable change, which has a major impact on patients and their wellbeing.

Patients with wounds represent an extremely vulnerable population. The case reports and clinical series coming out of Europe and China suggest that the factors associated with poor prognosis from COVID-19 are: older age, hypertension, chronic lung disease, diabetes and obesity. Patients with these disease symptoms or diagnosis fall into the same group that has an increased risk of developing chronic wounds.

The above poses unique challenges to providing good care to patients with active skin wounds. Patients with wounds have higher rates of ER visits, length-of-stay, amputation, and healthcare costs. When not treated adequately, it is likely that the condition might worsen and the patient need hospitalization. The great dilemma that is now at play is that these patients are considered high-risk if they are affected by COVID-19, however, they’re also considered high-risk for amputations, or even death, if their wound care immediately stops.

The Alliance of Wound Care Stakeholders poses that a notable difficulty in coordinating wound care for patients is the high number of places where wound patients receive care including: hospital inpatient, hospital outpatient, emergency departments, surgical centers, skilled nursing facilities, physician offices, and in the home[1].


What is needed are temporary regulatory waivers and new rules to give flexibility to wound care clinicians to provide necessary (and at times life and limb saving) procedures and products to treat their patients in light of the COVID-19 pandemic. In a pandemic model of care with shifting sites of care and reduced access and utilization, the major goal must be to reduce wound and diabetic foot-related hospitalizations and exposure to patients at risk for death from COVID-19.

This shift means that efficient wound management has to be paramount. It helps to reduce the burden on the health system and keeps our patients safe.

DEBx Medical aims to facilitate this process. DEBRICHEM is a novel desiccant gel for chemical debridement. The product is intended to eliminate the biofilm and remove the infection in up to 60 seconds. The procedure can be carried out by a trained healthcare professional in any medical setting: hospital, nursing home or home care.

During the pandemic, patients are safer at home and DEBx Medical enables them to be treated there where they’re the safest. With this we reduce the pressure on healthcare, we do not expose patients to unnecessary risks and more importantly: we can continue care for patients with wounds.